Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | PDE8B | O95263 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14934749 | 0.95 | HSD17B10 (0.46) | ATMPDE8BHSD17B10CHEK2SMN1; SMN2 | |
| SCHEMBL841886 | 0.95 | HSD17B10 (0.46) | ATMPDE8BHSD17B10CHEK2SMN1; SMN2 | |
| SCHEMBL33526612 | 0.95 | HSD17B10 (0.46) | ATMPDE8BHSD17B10CHEK2SMN1; SMN2 | |
| SCHEMBL190190 | 0.88 | PDE8B (0.47) | ATMPDE8BKDM1AHSD17B10HPGD | |
| SCHEMBL1551631 | 0.87 | ATM (0.51) | ATMPDE8BKDM1AHSD17B10CHEK2 | |
| SCHEMBL2345014 | 0.87 | ATM (0.51) | ATMPDE8BKDM1AHSD17B10CHEK2 | |
| SCHEMBL2687901 | 0.87 | ATM (0.60) | ATMPDE8BKDM1AHSD17B10CHEK2 | |
| SCHEMBL20828130 | 0.87 | ATM (0.60) | ATMPDE8BKDM1AHSD17B10CHEK2 | |
| SCHEMBL20828126 | 0.87 | ATM (0.60) | ATMPDE8BKDM1AHSD17B10CHEK2 | |
| SCHEMBL2354644 | 0.87 | ATM (0.51) | ATMPDE8BKDM1AHSD17B10CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132449-A1 | NOVEL COMPOUNDS FOR HOST DIRECTED ANTIVIRAL STRATEGY | SORBONNE UNIVERSITE (FR) | 2025-06-26 | — | — | WO | disclosed |
| CN-105073742-A | Flap modulators | JANSSEN PHARMACEUTICA NV | 2015-11-18 | — | — | CN | disclosed |
| EP-2585460-B1 | QUINOLIZIDINE AND INDOLIZIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2585460-A1 | QUINOLIZIDINE AND INDOLIZIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-01 | — | — | EP | disclosed |
| CN-101481380-B | Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof | ZHEJIANG MED XINCHANG PHARM | 2012-10-17 | — | — | CN | disclosed |
| US-8143273-B2 | Quinolizidine and indolizidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143273-B2 | Quinolizidine and indolizidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| CN-101481380-A | Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof | ZHEJIANG MEDICINE CO LTD (CN) | 2009-07-15 | — | — | CN | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007134298-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040192673-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2004-09-30 | — | — | US | disclosed |
| EP-1435955-A2 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SmithKline Beecham P.L.C. (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2002089800-A2 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | ATM 321/4885PDE8B 3629/4885KDM1A 1204/4885 |
| US-20040192673-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | ATM 4586/4885PDE8B 3067/4885KDM1A 1371/4885 |
| US-20070299258-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | ATM 1972/4885PDE8B 4207/4885KDM1A 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.